Company record · updated August 5, 2026
NexImmune, Inc.: 1 valuation observation from SEC filings
Every row below names the filing it came from. Coverage for this company runs January 19, 2021 to January 19, 2021.
1observations
1source filings
1verified rows
2021-01-19most recent as-of date
Source rails for this company: S-1 charter round (1).
| As of | Measure | Value | Reported by | Tier | What the filing says | Accession |
|---|---|---|---|---|---|---|
| 2021-01-19 | Series A-3 price per share | 0.3523 USD | — | VERIFIED | "Original Issue Price" defined for Series A-3 | 000119312521011521 |
Reading these figures
A fund mark is the filer's own fair-value estimate at a quarter end, not a transaction price, and two filers can reach different values for the same date. A charter round price is the issue price of that series at issuance. Neither is a current market price. The capabilities page states the full limits.